











Isoflavone Pharmacology
$\Box$ •Isoflavones (IF) act a weak estrogenic compounds. Are essentially
$\square$ •IF are competitive inhibitors of estrogen. If estrogen is high
$\square$ (premenopause), then will displace; if low (postmenopause) then will
$\square$ be an estrogen agonist.
$\square$ •Bind to estrogen receptor B (bone,vascular) better than ER-A
$\square$ (reproductive)
$\square$ •Have effects other than receptor action. Decrease aromatase, 3 B
and 17B-hydroxysteroid dehydrogenase, enzymes that convert
$\square$ •Are antioxidants
$\square$ •Japanese consume 30-40mg isoflavones/d; USA consumes little.
$\Box$ •Japanese women have lower breast cancer and menopause problems

Isoflavones (continued)	
Product Baw soybeans	mg isoflavones/100g ~100
Soy protein	100-300
Soy milk Soy flour	10 199
Cooked soybeans Tempeh	55 44
Tofu Soy poodles	31 o
Soy noones	7



Soy Effects on Heart Disease Risks

•Soy diets associated with normalization of lipid profiles

•Decreased total cholesterol (~9%), LDL (~13% decrease), increased HDL(small), triglycerides (~10% decrease) improved artierial dilation and compliance

•Soy modestly lowers BP

•In animal studies, soy without isoflavones did not affect lipids

•FDA now allows foods with 6.25g of soy protein per serving to state "consuming 25g of soy protein daily, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease"

•May need 20-50g/day of soy in diet for benefit

•Isoflavones alone may not work













Yam- is a scam

 Topical progesterone- works but risks same as HRT?



ginseng which is dried only

•History

•Chemistry-ginsenosides, a series of steroid glycosides. The ratio of these differ between Panax sp.





# Bottom Line

- pick a good product
- maybe useful in diabetes and in geriatric populations
- watch for drug interactions with narrow therapeutic index drugs



## Black Cohosh

Botany

- Cimicifuga racemosa. A tall perennial shrub in NE USA; roots and rhizomes used
- History
  - Used by Native Americans for women's health problems and a variety of other uses; A component of Lydia Pinkham's elixir,
  - In Europe a special black cohosh extract has been used since the 1950s for symptoms of menopause and PMS
- Chemistry
  - Contains phytosterin, salicylic acid, tannins, and triterpine glycosides that may be important for activity
  - The triterpine glycosides include acetin, 27deoxyacetin, and cimicifugoside



### Pharmacology

•black cohosh seems to lack estrogen activity in vivo; no effect on uterus (Liske et al. J Women's Health and Gender Based Med. 2002;11:163-174); SERM; mild stimulation of estrogen receptors B.

•May have central CNS effect on serotonin receptor

•Does not seem to stimulate estrogen receptor dependant tumors in animals or in vitro tumor cell growth. Humans?



•reduce symptoms associated with menopause

•relieve symptoms of menopause associated with tamoxifen therapy

•PMS

•dysmenorrhea

•hasten childbirthing

#### •Evidence for relief of menopausal symptoms

•Early studies with Remifemin show support for reducing hot flashes, etc in menopause

•well designed recent studies indicate benefit and SERM-like activity







	ed. One study showed no bene	efit		
•Jacobson et al. J Clin Oncol 2001;19:2739-2745 n=85; cohosh product NOT DESCRIBED				
•Munoz and Pluchino. Maturitas 2003;44:S59-S65. N=136; cohosl 20mg/d Menofem <sup>®</sup> for 12 months.				
•Table 4				
Table 4				
Table 4 Hot flushes	reduction by CR BNO 1055			
Table 4 Hot flushes Hot flushes	reduction by CR BNO 1055 Usual-care group <sup>a</sup> ( $n = 46$ )	Intervention group <sup>b</sup> (n = 90)		
Table 4 Hot flushes Hot flushes Severe	reduction by CR BNO 1055 Usual-care group <sup>a</sup> ( $n = 46$ ) 34 (73.9%)	Intervention group <sup>b</sup> ( $n = 90$ ) 22 (24.4%)		
Table 4 Hot flushes Hot flushes Severe Moderate	reduction by CR BNO 1055 Usual-care group <sup>a</sup> ( $n = 46$ ) 34 (73.9%) 12 (26.1%)	Intervention group <sup>b</sup> ( <i>n</i> = 90) 22 (24.4%) 26 (28.9%)		
Table 4 Hot flushes Hot flushes Severe Moderate None	reduction by CR BNO 1055 Usual-care group <sup>a</sup> ( <i>n</i> = 46) 34 (73.9%) 12 (26.1%)	Intervention group <sup>b</sup> ( <i>n</i> = 90) 22 (24.4%) 26 (28.9%) 42 (46.7%)		
Table 4 Hot flushes Hot flushes Severe Moderate None a Tamoxi	reduction by CR BNO 1055 Usual-care group <sup>a</sup> ( $n = 46$ ) 34 (73.9%) 12 (26.1%) –	Intervention group <sup>b</sup> ( <i>n</i> = 90) 22 (24.4%) 26 (28.9%) 42 (46.7%)		

## Safety

 •GI upset, headache, dizziness possible

•due to possible estrogenic effects, use with caution pregnancy

•in vitro does not stimulate breast cancer cells (in contrast to soy isoflavones) but in vivo the risk is uncertain.

•2 case reports of severe liver toxicity (causal?)

### Products

•Remifemin (SK Beecham) is a good product that has been used su contain •1 BID used successfully in controlled trials; it is standardized to contain 1mg of 27-deoxyacetin per 20mg tablet.

#### **Black Cohosh** ■ Summary • Efficacy: reasonable evidence for benefit for relief of menopausal symptoms. Mixed evidence for relief of tamoxifen adverse effects. ◆ Safety: good but a few case reports of liver toxicity. Safety in women with existing breast cancer is uncertain. Drug interactions: weak 2D6 induction? Product selection: standardized root extract; 20mg BID; Remifemin is the best tested. • Questions remaining include • What is the risk in breast cancer? • What is the risk for hepatotoxicity?











ר I		No of resp	onders	(95% confidence		
	Trial	lypericum	Control	interval)	Rate ratio (95% confidence interval)	
				0.1	1 10	10
Linde et al.	Placebo controlled trials of	single nre	narations	L		
N (T 21b 252	Halama 1991*12	10/25	0/25	21.00 (1.30 to 340.03)	o	
SMJ 318: 253-	Hansgen 1994#11	27/34	9/38	3 35 (1.85 to 6.08)		
	Hühner 1994*15	14/20	9/20	1.56 (0.89 to 2.73)	+	
58, 1996	Lehri 1993*17	4/25	2/25	2.00 (0.40 to 9.95)		
-,	Schmidt 1993*23	20/32	6/33	3 44 (1 59 to 7 44)		
	Sommer 1994*24	28/50	13/55	2.37 (1.39 to 4.04)		
	Osterheider 1992*18	0/23	0/24	1.04 (0.02 to 50.43) -	b	
	Quandt 1993*19	29/44	3/44	9.67 (3.18 to 29.42)		
	Schlich 1987*21	15/25	3/24	4.80 (1.59 to 14.50)		
	Schmidt 1989*22	10/20	4/20	2 50 (0.94 to 6.66)		
	Hoffmann 1979+14	19/30	3/30	633 (209 to 1917)		
	König 1993+16	29/55	31/57	0.97 (0.69 to 1.37)		
	Reb 1992*20	20/25	11/25	1.82 (1.12 to 2.95)	1	
	Summary rate ratios	20/25	11/25	1.02 (1.12 00 2.75)		
	Fixed effects	225/408	94/420	194 /160 to 234)	0	
	Random effects	220/100	111120	2.67 (1.78 to 4.01)	-0-	
	Placebo controlled trial of co	ombinatio		2.07 (1.70 (0 4.01)		
	Ditzler 1994±25	20/30	10/30	2 00 /1 14 to 3 52)		
	Trials comparing single prop	arations	nd anoth	2.00 (1.14 (0 3.32)		
	Harrar 1994*27 (v magratiline)	27/51	20/51	0.96 (0.67 to 1.39)		
	Vorbach 1994*29 (vimipromine)	47/67	20/31	1 15 (0.87 to 1.58)	I-	
	Reremann 1993*26 // amitruptiling	1 32/40	28/40	1.15 (0.87 to 1.53)	0-	
	Summer ate atter	52/40	20/40	1.14 (0.03 (0 1.46)	Ĩ.	
	Fixed effects	101/159	03/150	1 10 (0.93 to 1.21)	L.	
	Random effects	101/130	73/137	1.10 (0.73 to 1.31)	E.	
	Trials comparing combination	n of hund	ricum an	d valeriana with anoth	an druga	
	Knighel 1999#32 (u amitmostiling)	57/00	53/03	U valeriana with anoth	er drug	
	Stores 1995+33 (u designamine)	31/50	14/50	1.12 (0.71 to 1.37)		
	Steger 1903+** (V desipramine)	31/30	14/50	2.21 (1.35 to 3.63)		
	Summary rate ratios	00/120	22/122	1.25 (1.02 1.52)	6	
	Pixed effects	88/130	00/132	1.25 (1.03 to 1.53)		
	Kandom effects			1.52 (0.78 to 2.94)	T~	
	* Hamilton rating scale for depres	sion				
	+ Global assessment.					
	+ Clinical global impression index.					

	St.	John's Wort					
	Linde	et al conclusions: more effective than placebo, similar to standard drugs					
	Modia	al Lattar Oat 20, 1007					
	he he	al Letter Oct 20, 1997 tter Jonger studies needed doses unknown					
	V DC	tter, longer studies needed, doses unknown					
Woelk et al. BMJ 321:536-539, 2000. SJW same as imipramine with few adverse effects in multicentered German study (n=324) in patients with r moderate depression							
	Brenner et al. Clin Ther 22:411-419, 2000. SJW same as sertraline in double blind, randomized study (n=30) with mild to moderate depression						
	Schra fluoxe patien	chrader et al. Int Clin Psychopharmacol 15:61-68,2000. SJW same as loxetine with fewer adverse effects in multicentered German study (n=240) in litients with mild to moderate depression					
	Szege	di. A et al. BMJ 2005:330:503. SIW same as paroxitine with fewer					
	adver	se events. N=244					
		HAM-D difference intention-to-treat					
		10					
		5 • 8					
		0					
		2 -5 C C					
		eg -15					
		-20 8					
		-25					
		-30 °					
		-35					
		Hypericum Fluoxetine					
		Non-outlier minima					
		25% • Median					
		• Outliers					
		intention-to-treat.					
		Schrader et al., Int J Clin Psychopharmacol 15:61-68,2000					
		I					



Reuters Medical News St. John's Wort Equivalent to Placebo For Treatment of Depression

CHICAGO, May 17 (Reuters Health) - Patients with depression respond equally well to St. John's wort and placebo, according to study results presented here during the annual meeting of the American Psychiatric Association. :P ci

Researchers from Vanderbilt University, Nashville, Tennessee, discussed the results of one of the first large, government-funded projects to look into the effectiveness of St. John's wort. The team, led by Dr. Richard Shelton, conducted an 8-week double-blind study of 200 patients with major depression from 11 university medical centers.

For at least 4 weeks, patients used 900 mg/day of St. John's wort or placebo. If response was inadequate, the dose of St. John's wort was increased to 1,200 mg/day. Few patients discontinued treatment due to side effects from St. John's wort, but the results of interim analysis showed that the herbal preparation was no more effective than placebo.













H	ypericin and Hyperforin in Eight Brands of St.					
Jo	ohn's Wort					
De	Los Reyes and Koda, Am J Health-syst Pharm 59:545-547.2002					
	◆ <u>Product</u> -	hypericin (%)	<u>hyperforin (%)</u> *			
	Hyperifin	0.29	1.89			
	PNC	0.12	0.20			
	Brite-Life	0.22	1.16			
	ShopKo	0.26	0.05			
	Shurfine	0.17	0.29			
	YourLife	0.28	0.19			
	Nature's Balance	0.03	0.01			
	Natrol	0.25	0.48			
	* Usually want 0.3% hypericin and 1% hyperforin					